Research on BRCA2 carriers has demonstrated a correlation between the presence of BRCA2 and an increased incidence of prostate cancer, a younger age at diagnosis, a higher prevalence of clinically significant prostate cancer, and a more aggressive disease course. This evidence concerns the gene BRCA2 and prostate cancer.